端粒酶激活与上皮性卵巢癌化疗敏感性及其预后的关系

Relationship between telomerase and sensitivity to chemotherapy and prognosis in ovarian epithelial carcinoma.

目的 探讨端粒酶活性水平对卵巢化疗疗效及预后影响。方法 以TRAP -PCR -ELISA法检测卵巢癌组织中端粒酶活性 ;以MTT法检测卵巢癌细胞对CDDP、ADM敏感。结果 2 2例卵巢癌组织中 ,端粒酶阴性者 3例 ( 13 64%) ,阳性者 19例 ( 86 3 6%)。 8例端粒酶活性高于 2U者 ,PAC方案化疗有效者 5例 ( 62 5 %) ,11例端粒酶活性低于 2U者 ,化疗均有效 ( 10 0 %)。端粒酶活性高于 2U者 ,进展与复发或死亡 5例 ( 62 5 %) ,而端粒酶活性低于 2U者仅 1例出现复发 ,无死亡。结论 随着端粒酶活性增高 ,卵巢癌对CDDP、ADM敏感性下降。

Objective To study the relationship between activity of telomerase and sensitivity to chemotherapy and prognosis in ovarian carcinoma.Methods TRAP-PCR-ELISA was used to test telomerase in ovarian carcinoma.The sensitivity to CDDP and ADM was detected by MTT.Results Of 22 ovarian carcinoma cases,no telomerase activity could be detected in 3 cases(13^64%),detectable in 19 cases(86.36%).The telomerase activity greater than 2U were 8(42.11%),1-2U were 7(36.84%),and lower than 1U were 4(21.05%).5 cases(62.5%) whose telomerase activity greater than 2U were sensitive to PAC,but all 11 cases whose telomerase activity lower than 2U were sensitive to PAC.5 cases(62.5%) were progress and recurrent or dead among the cases whose telomerase activity was greater than 2U,whereas only 1 case relapsed among those whowe telomerase activity was lower than 2U,no dead case.Conclusion With the enhancement of telomerase activity,the sensitivity to CDDP and ADM decreases in ovarian carcinoma.